Investigation of the Impact of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Serum B-type Natriuretic Peptide (BNP) Level of Diabetic Patients With Congestive Heart Failure.
Overview
- Phase
- Phase 4
- Intervention
- Suspending DPP-4 inhibitor, in outpatient service
- Conditions
- Heart Failure
- Sponsor
- Mitsui Memorial Hospital
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Serum BNP level with and without DPP-4 inhibitor use.
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
We thought to investigate the influence of DPP-4 inhibitor on the serum BNP level of diabetic patients with congestive heart failure. This study consists of two protocols. In the first protocol, diabetic patients with high level of serum BNP (100-2000 pg/ml) receiving outpatient treatment with any type of DPP-4 inhibitor at our institution will be enrolled. After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again. In the other protocol, diabetic patients who were hospitalized due to heart failure were enrolled. DPP-4 inhibitor will be started (if the patient is not taking a DPP-4 inhibitor) or suspended (if the patient is taking a DPP-4 inhibitor) after stabilization of heart failure, and serum BNP will be measured before and after the drug administration or suspension.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetes patient with congestive heart failure under treatment with DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) .
- •High serum BNP (100-2000pg/ml).
- •Patients who have given informed consent to participation in the study.
Exclusion Criteria
- •HbA1c over 9.0%.
- •Patients who changed medication within 1 months before inclusion.
- •Judged as ineligible by clinical investigators.
- •Hospitalization arm
- •Inclusion Criteria:
- •Type 2 diabetes patient who were hospitalized for congestive heart failure.
- •Patients who have given informed consent to participation in the study.
- •Exclusion Criteria:
- •Patients on insulin therapy.
- •Judged as ineligible by clinical investigators.
Arms & Interventions
Outpatient arm
After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
Intervention: Suspending DPP-4 inhibitor, in outpatient service
Hospitalization arm 1
After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
Intervention: Starting DPP-4 inhibitor after treatment of heart failure
Hospitalization arm 2
After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
Intervention: Suspending DPP-4 inhibitor after treatment of heart failure
Outcomes
Primary Outcomes
Serum BNP level with and without DPP-4 inhibitor use.
Time Frame: 3 days to 2 months
In the outpatient arm, changes in serum BNP level measured 1 month after suspension of DPP-4 inhibitor, and 1month after resumption of the DPP-4 inhibitor will be analyzed. In the hospitalization arm, serum BNP before and 2-3 days after the initiation of DPP-4 inhibitor will be measured and compared.
Secondary Outcomes
- Heart failure hospitalization(2 months)
- Cardiovascular death(2 months)
- All cause mortality(2 months)
- Worsening heart failure(3 days)
- Echocardiographic measures (Changes in echocardiographic measures during the study period.)(3 days to 2 months)
- Other neurohormonal factors (Changes in plasma renin, aldosterone, serum stromal cell-derived factor 1 alpha, serum active glucagon-like peptide-1, serum active glucose-dependent insulinotropic polypeptid)(3 days to 2 months)